WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.
作者信息
Cohan Deborah, Mwesigwa Julia, Natureeba Paul, Aliba Luwedde Flavia, Ades Veronica, Plenty Albert, Kakuru Abel, Achan Jane, Clark Tamara, Osterbauer Beth, Kamya Moses, Havlir Diane
出版信息
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):e101-3. doi: 10.1097/QAI.0b013e31828011ca.
Abstract
摘要
相似文献
1
WHO option B+: early experience of antiretroviral therapy sequencing after cessation of breastfeeding and risk of dermatologic toxicity.世界卫生组织B+方案：停止母乳喂养后抗逆转录病毒治疗顺序的早期经验及皮肤毒性风险
J Acquir Immune Defic Syndr. 2013 Mar 1;62(3):e101-3. doi: 10.1097/QAI.0b013e31828011ca.
2
Efavirenz-Based Antiretroviral Therapy Among Nevirapine-Exposed HIV-Infected Children in South Africa: A Randomized Clinical Trial.南非接受奈韦拉平治疗的HIV感染儿童中基于依非韦伦的抗逆转录病毒疗法：一项随机临床试验。
JAMA. 2015 Nov 3;314(17):1808-17. doi: 10.1001/jama.2015.13631.
3
Lack of effect from a previous single dose of nevirapine on virologic and immunologic responses after 6 months of antiretroviral regimens containing either efavirenz or lopinavir-ritonavir.先前单次服用奈韦拉平对含依非韦伦或洛匹那韦/利托那韦的抗逆转录病毒方案治疗 6 个月后的病毒学和免疫学应答无影响。
Pharmacotherapy. 2011 Feb;31(2):158-63. doi: 10.1592/phco.31.2.158.
4
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.洛匹那韦/利托那韦与依非韦伦为基础的抗逆转录病毒疗法对乌干达感染HIV的孕妇的疗效及安全性比较
AIDS. 2015 Jan 14;29(2):183-91. doi: 10.1097/QAD.0000000000000531.
5
Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.在乌干达和马拉维，与未感染 HIV 的未暴露儿童相比，产前和产后抗逆转录病毒暴露对 HIV 暴露和未感染儿童的神经发育影响：一项前瞻性队列研究。
Lancet HIV. 2019 Aug;6(8):e518-e530. doi: 10.1016/S2352-3018(19)30083-9. Epub 2019 May 20.
6
Easier said than done: World Health Organization recommendations for prevention of mother-to-child transmission of HIV-areas of concern.说起来容易做起来难：世界卫生组织预防母婴传播艾滋病毒的建议——关注领域。
AIDS Res Hum Retroviruses. 2011 Aug;27(8):807-8. doi: 10.1089/AID.2010.0296. Epub 2011 Jan 17.
7
Antiretroviral therapies in women after single-dose nevirapine exposure.女性单次奈韦拉平暴露后的抗逆转录病毒治疗。
N Engl J Med. 2010 Oct 14;363(16):1499-509. doi: 10.1056/NEJMoa0906626.
8
Triple antiretroviral compared with zidovudine and single-dose nevirapine prophylaxis during pregnancy and breastfeeding for prevention of mother-to-child transmission of HIV-1 (Kesho Bora study): a randomised controlled trial.三重抗逆转录病毒治疗与齐多夫定和单剂量奈韦拉平预防方案在妊娠期和哺乳期用于预防 HIV-1 母婴传播的比较（肯尼亚母婴传播预防研究）：一项随机对照试验。
Lancet Infect Dis. 2011 Mar;11(3):171-80. doi: 10.1016/S1473-3099(10)70288-7. Epub 2011 Jan 13.
9
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.2002-2009 年在欧洲和北美开始接受抗逆转录病毒治疗的 HIV 阳性患者的首次抗逆转录病毒治疗方案的耐久性及改变、中断或死亡的危险因素。
AIDS. 2013 Mar 13;27(5):803-13. doi: 10.1097/QAD.0b013e32835cb997.
10
A randomized controlled trial to assess safety, tolerability, and antepartum viral load with increased lopinavir/ritonavir dosage in pregnancy.一项评估安全性、耐受性和产前病毒载量的随机对照试验，在妊娠期间增加洛匹那韦/利托那韦剂量。
AIDS Patient Care STDS. 2013 Nov;27(11):589-95. doi: 10.1089/apc.2013.0159. Epub 2013 Oct 19.
引用本文的文献
1
Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study.2000 年至 2015 年巴西感染 HIV 的孕妇接受抗逆转录病毒治疗的不良反应：一项队列研究。
BMC Infect Dis. 2018 Sep 27;18(1):485. doi: 10.1186/s12879-018-3397-x.
本文引用的文献
1
Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda.评估联合抗逆转录病毒疗法在乌干达预防母婴传播艾滋病毒的成本效益。
Bull World Health Organ. 2012 Aug 1;90(8):595-603. doi: 10.2471/BLT.11.095430.
2
Adverse events in a cohort of HIV infected pregnant and non-pregnant women treated with nevirapine versus non-nevirapine antiretroviral medication.在一组接受奈韦拉平与非奈韦拉平抗逆转录病毒药物治疗的 HIV 感染孕妇和非孕妇中发生的不良事件。
PLoS One. 2010 Sep 7;5(9):e12617. doi: 10.1371/journal.pone.0012617.
3
Liver toxicity after switching or simplifying to nevirapine-based therapy is not related to CD4 cell counts: results of the TOSCANA study.改用或简化为基于奈韦拉平的治疗方案后的肝脏毒性与CD4细胞计数无关：托斯卡纳研究结果
HIV Clin Trials. 2010 Jan-Feb;11(1):11-7. doi: 10.1310/hct1101-11.
4
Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy.开始含奈韦拉平的抗逆转录病毒治疗的患者中导致治疗受限毒性的危险因素。
AIDS. 2009 Aug 24;23(13):1689-99. doi: 10.1097/QAD.0b013e32832d3b54.
5
Switching from suppressive protease inhibitor-based regimens to nevirapine-based regimens: a meta-analysis of randomized controlled trials.从基于蛋白酶抑制剂的抑制性治疗方案转换为基于奈韦拉平的治疗方案：随机对照试验的荟萃分析。
HIV Med. 2008 Oct;9(9):747-56. doi: 10.1111/j.1468-1293.2008.00627.x. Epub 2008 Jul 21.
6
Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
HIV Med. 2008 Aug;9(7):514-8. doi: 10.1111/j.1468-1293.2008.00597.x. Epub 2008 Jun 28.
7
Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia: a randomized, controlled study.对血脂异常的HIV-1感染患者进行依非韦伦换用奈韦拉平的研究：一项随机对照试验
Clin Infect Dis. 2007 Jul 15;45(2):263-6. doi: 10.1086/518973. Epub 2007 Jun 6.
8
A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.一项随机对照试验，旨在研究病毒载量检测不到的患者从蛋白酶抑制剂转换为奈韦拉平的疗效和安全性。
HIV Med. 2005 Sep;6(5):353-9. doi: 10.1111/j.1468-1293.2005.00320.x.
9
Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia.用奈韦拉平或依非韦伦替代蛋白酶抑制剂与降脂治疗对血脂异常的管理作用比较
AIDS. 2005 Jul 1;19(10):1051-8. doi: 10.1097/01.aids.0000174451.78497.8f.
10
Dose escalation or immediate full dose when switching from efavirenz to nevirapine-based highly active antiretroviral therapy in HIV-1-infected individuals?在HIV-1感染个体中，从依非韦伦转换为基于奈韦拉平的高效抗逆转录病毒疗法时，是逐步增加剂量还是立即给予全剂量？
AIDS. 2004 Feb 20;18(3):572-4. doi: 10.1097/00002030-200402200-00029.
Zotero 插件